Myelodysplastic syndromes: who works on it

One card per institution. Pick a target or a country to narrow the list.

• All targets
• TP53 6
• IDH 12
• FLT3 6
• BCL-2 4
• CD19 5
• CD33 3
• RUNX1 0
• CD123 3
• JAK 3
• PARP 0
• TIM-3 0
• ABL1 0
• KMT2A 1
• CD47 0
• NPM1 2
• PD-1 1
• IL-1 2
• NLRP3 1
• ERK 0
• EZH2 0
• NRAS 0
• RAS 0
• SGLT2 1
• AKT 0
• CD20 1
• CD38 2
• CSF1R 2
• GLP-1 0
• IL-6 1
• PD-L1 0
• PI3K 1
• STING 1
• ALK 0
• AMPK 0
• AR 0
• ATM 0
• BCMA 1
• BRAF 0
• BRCA1 0
• BRCA2 0
• BTK 0
• CCR5 0
• CD22 1
• CD40 0
• COX-2 0
• CTNNB1 0
• GPRC5D 1
• GPX4 0
• HIF-1 0
• IL-15 1
• IL-17 0
• KIT 0
• KRAS 0
• MAPK 0
• MYC 0
• PRMT5 0
• RB1 0
• STAT3 0

24 of 65+ institutions, ordered by recent publications and open trials. This is not a ranking of quality.

Funded research projects that name this disease in their title, terms or summary and have not ended yet: who is funded, where, how much and until when. Organisations only; the funder's page has the details.

• NIH NCI · R44

  A Phase 2 Study of SX-682 in Combination with Nivolumab and Relatlimab in Melanoma Patients

  Syntrix Biosystems, Inc.· Auburn, United States· US$406,500 awarded in fiscal year 2026· until Aug 2027

• NIH NCI · DP2

  Single-molecule, Single-cell profiling of chromatin protein-protein interactions.

  Van Andel Research Institute· Grand Rapids, United States· US$912,000 awarded in fiscal year 2026· until Aug 2031

• NIH NIDDK · R01

  Role of IL-1 beta signaling in stress erythropoiesis

  Pennsylvania State University, the· University Park, United States· US$641,869 awarded in fiscal year 2026· until May 2030

• NIH NHLBI · R01

  Mechanisms underlying germline predisposition to clonal hematopoiesis

  Albert Einstein College of Medicine· Bronx, United States· US$693,151 awarded in fiscal year 2026· until May 2031

• NIH NHGRI · R01

  A single-cell multiomics platform for studying genome structure and function

  University of Washington· Seattle, United States· US$796,114 awarded in fiscal year 2026· until Aug 2030

• European Commission (Horizon Europe) · HORIZON-TMA-MSCA-SE

  Towards novel approaches for Myelodysplastic Syndromes diagnosis to Strengthen Research Human Capital with Cross-Sectoral and Interdisciplinary Staff mobility (DiagMDS)

  Idryma Iatroviologikon Ereunon Akademias Athinon· Athina, Greece· EU contribution €1,322,640· until Sept 2030· 9 countries

• European Commission (Horizon 2020) · ERC-COG

  Identifying spatial determinants of immune cell fate commitment (ImmuNiche)

  Julius-Maximilians-Universitat Wurzburg· Wuerzburg, Germany· EU contribution €1,997,500· until Dec 2026

7 of 170 running projects, newest first. Listed amounts together: US$120.9m + €3.3m.

Sources: NIH RePORTER (U.S. National Institutes of Health, public domain) and CORDIS (European Commission, CC BY 4.0). Changes: filtered by disease, organisations matched to ROR.

Terminated, withdrawn and suspended trials with the reason the sponsor gave in the registry, quoted word for word.

• Withdrawn

  A Phase 2 Study Evaluating Olutasidenib in Combination With Hypomethylating Agents in Patients With IDH1-mutated Higher-risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Advanced Myeloproliferative Neoplasm

  NCT06597734· M.D. Anderson Cancer Center· Updated 5 Oct 2026

  “PI request”Registry text, quoted unchanged. Source

• Terminated

  A Study of CG-806 in Patients With Relapsed or Refractory AML or Higher-Risk MDS

  NCT04477291· Aptose Biosciences Inc.· Updated 7 Mar 2025

  “Change in corporate strategy”Registry text, quoted unchanged. Source

Trials whose registry record says individual participant data (IPD) will be shared.

• Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

  NCT06577441· National Cancer Institute (NCI)· Source

• Using the Anticancer Drug Olaparib to Treat Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome With an Isocitrate Dehydrogenase (IDH) Mutation

  NCT03953898· National Cancer Institute (NCI)· Source

• Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

  NCT07153497· National Cancer Institute (NCI)· Source

• Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

  NCT06465953· Institut de Recherches Internationales Servier· Source

• Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

  NCT03173248· Institut de Recherches Internationales Servier· Source

• Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

  NCT02074839· Institut de Recherches Internationales Servier· Source

• Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation

  NCT02632708· Institut de Recherches Internationales Servier· Source

Find publications on this disease by a MeSH method term, for example a sequencing or imaging method.

• Single-Cell Analysis 3
• CRISPR-Cas Systems 3
• Gene Expression Profiling 12
• Exome Sequencing 8
• Proteomics 2
• Metabolomics 1
• Mass Spectrometry 1
• Flow Cytometry 18
• Immunohistochemistry 1
• Liquid Biopsy 1
• Circulating Tumor DNA 1
• Xenograft Model Antitumor Assays 4
• Magnetic Resonance Imaging 8
• Machine Learning 8
• Deep Learning 3
• Cohort Studies 7

• A single-cell solution to a transplant mystery.

  Med, May 2026

• Imputing causality and clonal dynamics from single-cell transcriptomics in paroxysmal nocturnal hemoglobinuria.

  Leukemia, Apr 2026

• Prediction of myeloid malignant cells in Fanconi anemia using machine learning.

  PLoS One, Jan 2026

See which targets of this disease your abstract mentions, and go to the people working on them.